Cytokinetics, Incorporated

NASDAQ:CYTK

Biotechnology

Healthcare
$51.32 +3.86%

+$2.90 today

Market cap
$7.15B
Beta
0.43
P/E (TTM)
-11.6
EPS (TTM)
-$6.73
52W Low $31.99High $80.20

Volume 1.59M

Average 2.37M

CYTK Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Cytokinetics, IncorporatedNASDAQ: CYTK

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 132.09M shares rose 10.6% year over year, ahead of the +5.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 7.1% from the prior quarter. Over 3 fiscal years it compounded at +10.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +10.6% holds above the trailing-twelve-month pace of +5.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
132.09M+7.1% QoQ
Last fiscal yearDec 2025
120.1M+7.3% YoY
LTMJun 2026
124.44M+5.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.6%——
1 year+7.3%——
3-year CAGR+10.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
120.1M USD
Year-over-year change
+7.3%
4-year CAGR
+11.8%

Weighted Avg Shares (Diluted) vs competitors

How CYTK compares with its peers on the latest reported figures

  • CYTK's LTM Jun 2026 weighted avg shares (diluted) of 124.44M shares is the 2nd highest of the 3 companies compared; the peer median is 87.57M shares.
  • Its year-over-year change of +5.1% is the lowest of 2, against a peer median of +71.7%.
  • Over three fiscal years its annual growth of +10.2% compares with a peer median of +50.6%.
CYTK Competitors Peer median
Weighted Avg Shares (Diluted) for CYTK and competitors
Company Period LTM YoY 3-year CAGR
TNYATenaya Therapeutics, Inc.LTM Mar 2026158.02M +71.7%+50.6%
CYTKCytokinetics, IncorporatedLTM Jun 2026124.44M +5.1%+10.2%
RNAAtrium Therapeutics, Inc.FY202517.11M ——
KARDKardigan, Inc.—— ——
Peer median (excluding CYTK) 87.57M+71.7%+50.6%

Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue70.43M94.59M7.53M18.47M88.04M
Cost of Revenue159.94M240.81M330.12M339.41M10.13M
Gross Profit(89.51M)(146.23M)(322.59M)(320.93M)77.91M
Gross Margin-127.1%-154.6%-4284.1%-1737.2%88.5%
Research & Development159.94M240.81M330.12M339.41M405.9M
Selling, General & Admin96.8M177.98M173.61M215.31M284.27M
Operating Expenses96.8M177.98M173.61M215.31M690.17M
Depreciation & Amortization2.28M5.81M11.89M9.53M10.13M
EBITDA(183.71M)(331.99M)(456.68M)(493.48M)(774.83M)
EBITDA Margin-260.8%-351.0%-6064.9%-2671.2%-880.1%
Operating Income(186.31M)(324.2M)(496.21M)(536.25M)(612.26M)
Operating Margin-264.5%-342.8%-6589.7%-2902.7%-695.4%
Interest Income331K11.34M27.63M51.53M48.42M
Interest Expense29.33M51.16M57.67M86.51M103.87M
Other Income / Expenses(29M)(64.75M)(30.04M)(53.28M)(172.7M)
Income Before Tax(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Pre-Tax Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
Income Tax Expense00000
Net Income(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Net Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
EPS (Basic)(2.80)(4.33)(5.45)(5.26)(6.54)
EPS (Diluted)(2.80)(4.33)(5.45)(5.26)(6.54)
Weighted Avg Shares76.89M89.83M96.52M111.98M120.02M
Weighted Avg Shares (Diluted)76.89M89.83M96.52M111.98M120.1M

Cytokinetics, Incorporated

NASDAQ:CYTK

Intrinsic Alpha fair value

Locked

Current Price

$51.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.